Crowdonomics
All companies
Reflex logo

Reflex

Operating

Brightlamp, Inc.

Healthcare · Indianapolis, IN · Founded 2018

Five-second neurological vital

Post-money valuation ⓘ
$15.6M
As of Feb 2023 · from Reg CF Offering (2022) · pre-money + amount raised, not a traded price
Total raised
$65,754
Across 1 round since 2022
Latest share price
$2.37
Reg CF · Common Stock · Nov 2022 offering price

Financials

FY2020–FY2022 · from SEC filings · hover any figure for its source
$32K
−$266K
2020
$120K
$94K
2021
$132K
−$93K
2022
RevenueNet income — beside revenue when positive, below the line when a loss
Metric
FY2020 reviewed
FY2021 reviewed
FY2022 unaudited
Income statement
Revenue
$31,630
$120,372
$132,074
Cost of goods sold
$10,803
$14,004
$17,628
Gross margin
66%
88%
87%
Net income
-$266,093
$93,748
-$93,022
Taxes paid
$0
$0
$0
Balance sheet
Cash
$59,795
$41,047
$75,863
Accounts receivable
$0
$120,372
$132,074
Total assets
$59,800
$41,052
$75,868
Short-term debt
$88,536
$0
$0
Long-term debt
$752,500
$827,500
$902,500
Total liabilities
$841,036
$827,500
$902,500
Other
Headcount
—
4
4

Figures as reported by the issuer in the filing shown on hover. Each year’s pill shows the assurance level of its filed statements — audited, reviewed (CPA review, less than an audit), or unaudited, as the filing’s own report or certification states it. A dashed pill marked * is inferred instead: the SEC minimum for an offering that size, which the issuer may have exceeded. No pill means we couldn’t tell. Headcount is the filing’s point-in-time count, not a year-end average. Manually corrected figures are marked “Corrected”.

Valuation over rounds

Pre-money — the valuation set before each round’s money came in
$15.5M
pre-money
Reg CF · Common · Nov 2022

Blue bars are the pre-money valuation the company stated for a priced round.

Fundraising history

Raised $65.8K / $1.2MInvestors 51Post-money $15.6M

Team

2 people
Kurtis William SlussFounder
CEO & Director

Kurtis Sluss is an engineer, inventor, and TechCrunch Disrupt Alumnus. His background is in chemical engineering and organic chemistry from Purdue University with a focus on novel drug design and disease detection methods. An interest in advanced programming and its application in medicine led him to create a novel method to detect and classify cancerous proteins through machine learning. Now, Kurtis is translating this knowledge to neuro-biomechanical evaluations using a mobile phone. He leads Brightlamp as co-Founder and CEO to maintain the vision of creating affordable diagnostic technologies on a global scale.

Michael HeimsFounder
CFO & Director

Michael Heims serves as the Chief Financial Officer at brightlamp. Previously to brightlamp, Michael worked at Eli Lilly and Company as a Financial Analyst managing a budget of more than $200M. Michael left Lilly to join a role with a medium-sized private equity firm, where he grew a portfolio company from $2M in EBITDA to over $30M in less than 2 years by working as the sole acquisition advisor. While there, he contributed to a variety of aspects of due diligence of prospective companies, from quality of earnings to forecasting models, and everything in between.

Names and titles as disclosed on SEC Form C, StartEngine. Bios and photos come from the platform campaign page and may be out of date.

Reg CF annual-report compliance

Not requiredFiled Form C-TR (terminated reporting)

Filed 1 of 4 annual reports (FY2022–FY2025)

51 investors
holder-count proxy

Reg CF issuers must file a Form C-AR each year until a Rule 202(b) termination trigger is met.

SEC filings

  • Form C-TRApr 5, 20240001665160-24-000307
    EDGAR
  • Form C-ARApr 3, 20230001665160-23-000531
    EDGAR
  • Form C-UFeb 8, 20230001665160-23-000198
    EDGAR
  • Form CNov 8, 20220001665160-22-002888
    EDGAR
Source: ManualCIK 0001951399DEShare price $2.37

About this data. Figures are compiled from public sources — SEC EDGAR filings (Form C, C-AR, 1-A, 1-K) and funding-platform pages — and may be delayed, incomplete, or restated by the issuer. Financial statements are as reported by the issuer; each year is labeled with its assurance level (audited / reviewed / unaudited). A valuation cap is the conversion ceiling of a SAFE or convertible note, not an agreed company valuation; post-money figures are computed as pre-money plus amount raised and are not a traded price. Crowdonomics is not a broker-dealer, funding portal, or investment adviser; nothing here is investment advice or an offer to sell securities. Verify all figures against the linked EDGAR filings.